About us
Meet the Members of Our Pharmaceutical Research Company
Management and Board of Directors
Dr. John N. Bonfiglio
John N. Bonfiglio Ph.D. MBA and has over 30 years of experience in the biotech/pharmaceutical industry, Including over 20 years as a C-level executive in the biotech industry. He is currently a Board member for Avipero and an Executive Board member for Sequella, a US-based biotech company.
Dr. Bonfiglio started his career with 11 years at Allergan pharmaceuticals. Then, I spent three years at Baxter HealthCare before beginning a career in small biotech companies. Finally, I rose to the position of CEO at Peregrine Pharmaceuticals, where he turned around the financially strapped public company.
Dr. Bonfiglio was named COO at Cypress Bioscience while the company was reinventing itself as a neuro-pharmaceutical company. I then joined the Immune Response Corporation as CEO and was responsible for raising over $50M and restarting clinical research in HIV and MS areas.
As CEO at Argos Therapeutics, a privately held oncology company, he raised $35M through a series C financing. His tenure at Argos produced clinical data, which led to an IPO and subsequent financings.
Following Argos, he became President and CEO at Oragenics in Tampa, Fl. I completed two strategic deals with Intrexon Corporation, raised $29M, relisted the company on the NYSE: MKT, and refocused the company on the new novel and proprietary antibiotics.
Dr. Bonfiglio was the COO at TapImmune, where he was responsible for starting a clinical program, raising capital, and relisting the company on Nasdaq. The company is now known as Marker Therapeutics (MRKR -Nasdaq).
Dr. Bonfiglio has held independent Board positions at GT BioPharma (GTBP), Microlin, and Genprex (GNPX).
Robert F. “Bob” Marchesani Jr.
Bob Marchesani is president and principal consultant with Proventus Consulting LLC. This consulting company guides pharmaceutical and biotechnology companies in the oncology field on integrating prescriber, patient, and payer insights into the drug development process and the commercialization strategy to exceed business goals at launch and beyond.
Marchesani has 33 years of experience in the US and global pharmaceutical industry and has a comprehensive background in product development and brand strategy, international marketing, brand positioning and differentiation, launch strategy, and cross-functional/cross-geographical collaboration.
He demonstrated global brand building, launch excellence, and life-cycle management skills as global brand leader for ALIMTA® (pemetrexed), which achieved peak sales of $2.8 billion, excellent brand equity, and significance as Lilly’s top-selling product in 2014. He also demonstrated launch excellence, leveraging customer insights, and life-cycle management skills as a marketing leader on GEMZAR® (gemcitabine), which achieved peak sales of $1.7 billion in 2008.
And in his last role with Lilly, Marchesani demonstrated strategic product and brand development skills as global brand leader for Lilly’s VERZENIO® (abemaciclib), launched in 2017.
He is a member of the Board of Directors of Isofol Medical AB and a member of the board’s remuneration committee. Marchesani also serves as an adjunct MBA faculty member for the capstone strategy class and as an executive mentor in Butler University’s Lacy School of Business.
He earned an MBA in marketing and a bachelor’s degree in journalism and public relations. Marchesani is a member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He is active in community service and has served in volunteer leadership positions for several educational and community organizations.
https://www.linkedin.com/in/bobmarchesani/
Ehab Al-Jamal
Leadership – Account Management – Part of the C-suit as CIO – Consulting – Client Relationship Management – Enterprise Solutions – Roadmap Development – Stakeholder Relationships – Vendor Relationship Management – Contract Negotiations.
A highly skilled Director/CIO of IT solutions with 20+ years of experience maintaining security and stabilizing computing infrastructure, data management systems, and network communications.
I have a demonstrated track record of success as a Project/Program Manager, Solutions Architect, and Senior Applications Developer. My expertise includes security, integration, and software development, and I offer strategies that support the company’s goals, values, and vision for growth.
As an effective communicator, I am adept at building cohesive relationships with all levels of staff, management, clients, vendors, and key decision-makers. I also assist the company in achieving cutting-edge technology to remain competitive in any market. Throughout the entire program-project lifecycle, from presales/contract negotiation to the statement of work (SOW), vendor management, global development/implementation, and ongoing operations. Drive successes in business solution development, interfacing with executives, technology, and external specialists to align, refocus and execute project management on accelerated timeframes and within budget.
Trusted Partnership Award – Centegra Health System
Centegra Health System is one of our newest healthcare IT customers in Northern Illinois. Even though the relationship is less than two years, our team has already shown the value of our services with many successes. Through solid results of the account startup and completing several projects, IT has been viewed as a significant contributor towards improving quality and lowering delivery costs. As a result, Dell. A trusted partner to Centegra, we are all looking forward to building an excellent long-term relationship with this marquee healthcare organization.
Account of the year – Stanford
As a part of the management team, we were working on Operation, Integration efforts ts to automate processes and workflow, pull the staff needed into solution groups to maintain support, migrate all financial applications to a new state using EPIC, and also work on ensuring that Stanford is well positioned to get Certified for Stage 7). Recognized as Account of the Year, the achievements are highlighted as consistent with our overall objectives of transforming the industry with greater use of Information Technology with the completion of a multi-year transformation project using the Epic system. HIMSS Analytics recognized Stanford as a stage 7 recipient, the highest rating an organization can achieve. Paper charts are no longer used to deliver patient care and support the true sharing and use of patient data that ultimately improves process performance, quality of care, and patient safety. Along with the Epic project success, the account continued to progress towards customer satisfaction, with a 40% improvement over 2008. Associate satisfaction goals were exceeded with a 10% improvement year over year. Lastly, the Stanford account team realized an impressive 175% improvement in growth in 2009.
To achieve this, I collaborate with senior management and key stakeholders to analyze technology needs and deploy best-fit tools and solutions. For instance, during my recent engagement at USPI – OASIS, I helped build the hospital from the ground up by implementing end-to-end IT systems and equipment facility-wide. This advanced technology adoption later helped establish the hospital as #1 among regional orthopedic and spine surgery hospitals.
Dr. Nigel Barnes
Nigel has over 25 years experience of working in the city having been a director of Pharmaceutical research at ABN AMRO, First Vice President of Merrill Lynch European Healthcare Equity Research, a partner at Sudbrook Associates, a healthcare corporate advisory business, and a partner at WG Partners. He has a Ph.D. in pharmacology and has worked in the research laboratories of ICI (AstraZeneca) and Glaxo. In addition, he gained Sales and Marketing experience at Glaxo. Nigel has played an active role in a number of the leading corporate transactions, including a number of the major European sector mergers, IPO’s and capital raises.
Dr. Rehab AlJamal-Naylor
Officer-BSc, Ph.D.
Was a principal investigator and a senior research fellow at Edinburgh University’s Medical School. She has a long-standing interest in tissue remodeling and repair.
She was trained as a pharmacologist at Bradford University and SmithKline Beechams Cardiopulmonary Product Support Group. She then went on to receive further training and a Ph.D. in matrix remodeling and respiratory function at McGill University’s Meakins Christie Laboratories. She is the principal inventor of the research detailing the use of beta1 integrin in tissue repair and replicative senescence.
Dr. John Blenkinsopp
BPharm, MB ChB, GMC3301591
Studied Pharmacy at Bradford University and Medicine at Birmingham University. He has postgraduate qualifications in both management and Pharmaceutical Medicine. John has worked in all phases of drug development. He was a Clinical Research Physician at Hazleton Medical Research Unit (now Covance), Leeds, UK, a Phase 1 clinical research unit with 50 beds and over 40 studies completed each year. He has also worked for AstraZeneca, GlaxoSmithKline and Schering Plough.